![Barrie Charles Finnin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barrie Charles Finnin
Directeur/Membre du Conseil chez PolyActiva Pty Ltd.
Postes actifs de Barrie Charles Finnin
Sociétés | Poste | Début | Fin |
---|---|---|---|
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Barrie Charles Finnin
Anciens postes connus de Barrie Charles Finnin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ACRUX LIMITED | Directeur/Membre du Conseil | 01/01/1998 | 31/08/2011 |
Fondateur | 01/01/1998 | - | |
Therapeutic Goods Administration | Corporate Officer/Principal | - | - |
Statistiques
Internationale
Australie | 4 |
Opérationnelle
Director/Board Member | 2 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ACRUX LIMITED | Health Technology |
Entreprise privées | 2 |
---|---|
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Therapeutic Goods Administration |
- Bourse
- Insiders
- Barrie Charles Finnin
- Expérience